[EN] IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE TYROSINES KINASES RÉCEPTRICES
申请人:ASTEX THERAPEUTICS LTD
公开号:WO2009150240A1
公开(公告)日:2009-12-17
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
[EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
申请人:ASTEX THERAPEUTICS LTD
公开号:WO2009047506A1
公开(公告)日:2009-04-16
The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
[EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
申请人:ASTEX THERAPEUTICS LTD
公开号:WO2009047522A1
公开(公告)日:2009-04-16
The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE
申请人:Saxty Gordon
公开号:US20120035171A1
公开(公告)日:2012-02-09
The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
[EN] PGDH INHIBITORS AND METHODS OF MAKING AND USING<br/>[FR] INHIBITEURS PGDH ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
申请人:MYOFORTE THERAPEUTICS INC
公开号:WO2021151014A1
公开(公告)日:2021-07-29
Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.